Every headline mentioning Moderna from Yahoo Finance, MarketWatch and CNBC over the last 30 days, each scored for sentiment and importance. Updated automatically through the trading day.
Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.
The Dow Jones index falls Friday after a strong October jobs report. Nvidia stock gains after an AI trade rout.
Moby summary of Moderna, Inc.'s Q3 2026 earnings call
The company lifted its sales outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
These are some of the stocks posting the largest moves premarket.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Technology stocks sold off sharply last week amid growing concerns around artificial intelligence’s sustainability and debt woes.
The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
Moderna released full data on its closely watched cancer vaccine developed with Merck.
The stock fell 17% in one trading session.
These are the stocks posting the largest moves in early trading.
The S&P 500 and Nasdaq tumbled below 50-day lines as Meta led an AI stock rout. But the Warren Buffett market is thriving.
For questions about this article or underlying research, email help@trefis.com.
Moderna released full data on its closely watched cancer vaccine developed with Merck.
The S&P 500 and Nasdaq tumbled below 50-day lines as Meta led an AI stock rout. But the Warren Buffett market is thriving.
Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.
A ‘sell-the-news reaction’? The experimental treatment helped prevent the return of cancer or death in melanoma patients by 42% after two years.
Market Domination Host Brooke DiPalma tracks several of the day's top trending stock tickers, including Moderna (MRNA) plunging after the trial results for its melanoma vaccine were leaked, Elon Musk reportedly investing $1 billion in…
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.
Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.
Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.
This company made headlines with its coronavirus vaccine.
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.